Abstract
p<0.001). In addition, IFX levels were compared based on the phase of therapy (induction vs. maintenance) and antibody status (detectable vs. non-detectable) (Table 1). Conclusions: This study is to our knowledge the first analysis of IFX levels and ATI in pediatric patients with IBD utilizing the newly-available commercial electrochemilumescense assay. As expected, IFX levels were higher during induction compared to maintenance. In addition, we found a strong inverse relationship between IFX and ATI levels which suggests the important clinical potential of this tool in the treatment of IBD. Patients with elevated ATI are being studied longitudinally to determine whether ATI levels can be reduced by increasing IFX levels. In our population only 51% were on concomitant thiopurine or methotrexate, reflecting the concern of pediatric gastroenterologists for increased malignant potential. The authors report no conflict of interests. This study was internally funded and received no commercial support. Table 1. Infliximab levels based on phase of therapy and antibody status
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
